This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shinabarger, D. L.
Right arrow Articles by Buysse, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shinabarger, D. L.
Right arrow Articles by Buysse, J. M.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., Oct 1997, 2132-2136, Vol 41, No. 10
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

DL Shinabarger, KR Marotti, RW Murray, AH Lin, EP Melchior, SM Swaney, DS Dunyak, WF Demyan and JM Buysse
Infectious Diseases Research, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001-0199, USA.

The oxazolidinones are a new class of synthetic antibiotics with good activity against gram-positive pathogenic bacteria. Experiments with a susceptible Escherichia coli strain, UC6782, demonstrated that in vivo protein synthesis was inhibited by both eperezolid (formerly U-100592) and linezolid (formerly U-100766). Both linezolid and eperezolid were potent inhibitors of cell-free transcription-translation in E. coli, exhibiting 50% inhibitory concentrations (IC50s) of 1.8 and 2.5 microM, respectively. The ability to demonstrate inhibition of in vitro translation directed by phage MS2 RNA was greatly dependent upon the amount of RNA added to the assay. For eperezolid, 128 microg of RNA per ml produced an IC50 of 50 microM whereas a concentration of 32 microg/ml yielded an IC50 of 20 microM. Investigating lower RNA template concentrations in linezolid inhibition experiments revealed that 32 and 8 microg of MS2 phage RNA per ml produced IC50s of 24 and 15 microM, respectively. This phenomenon was shared by the translation initiation inhibitor kasugamycin but not by streptomycin. Neither oxazolidinone inhibited the formation of N-formylmethionyl-tRNA, elongation, or termination reactions of bacterial translation. The oxazolidinones appear to inhibit bacterial translation at the initiation phase of protein synthesis.


This article has been cited by other articles:

  • Locke, J. B., Hilgers, M., Shaw, K. J. (2009). Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700). Antimicrob. Agents Chemother. 53: 5265-5274 [Abstract] [Full Text]  
  • Paul-Satyaseela, M., Solanki, S. S., Sathishkumar, D., Bharani, T., Magesh, V., Rajagopal, S. (2009). In vitro antibacterial activities of a novel oxazolidinone, OCID0050. J Antimicrob Chemother 64: 797-800 [Abstract] [Full Text]  
  • Boumghar-Bourtchai, L., Dhalluin, A., Malbruny, B., Galopin, S., Leclercq, R. (2009). Influence of Recombination on Development of Mutational Resistance to Linezolid in Enterococcus faecalis JH2-2. Antimicrob. Agents Chemother. 53: 4007-4009 [Abstract] [Full Text]  
  • Baldoni, D., Haschke, M., Rajacic, Z., Zimmerli, W., Trampuz, A. (2009). Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection. Antimicrob. Agents Chemother. 53: 1142-1148 [Abstract] [Full Text]  
  • Skripkin, E., McConnell, T. S., DeVito, J., Lawrence, L., Ippolito, J. A., Duffy, E. M., Sutcliffe, J., Franceschi, F. (2008). R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance. Antimicrob. Agents Chemother. 52: 3550-3557 [Abstract] [Full Text]  
  • Wilson, D. N., Schluenzen, F., Harms, J. M., Starosta, A. L., Connell, S. R., Fucini, P. (2008). The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl. Acad. Sci. USA 105: 13339-13344 [Abstract] [Full Text]  
  • Condos, R., Hadgiangelis, N., Leibert, E., Jacquette, G., Harkin, T., Rom, W. N. (2008). Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis. Chest 134: 187-192 [Abstract] [Full Text]  
  • Foleno, B. D., Abbanat, D., Goldschmidt, R. M., Flamm, R. K., Paget, S. D., Webb, G. C., Wira, E., Macielag, M. J., Bush, K. (2007). In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 51: 361-365 [Abstract] [Full Text]  
  • Wang, W., White, R., Yuan, Z. (2006). Proteomic Study of Peptide Deformylase Inhibition in Streptococcus pneumoniae and Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 1656-1663 [Abstract] [Full Text]  
  • Kulkarni, K, Del Priore, L V (2005). Linezolid induced toxic optic neuropathy. Br J Ophthalmol 89: 1664-1665 [Full Text]  
  • Nagiec, E. E., Wu, L., Swaney, S. M., Chosay, J. G., Ross, D. E., Brieland, J. K., Leach, K. L. (2005). Oxazolidinones Inhibit Cellular Proliferation via Inhibition of Mitochondrial Protein Synthesis. Antimicrob. Agents Chemother. 49: 3896-3902 [Abstract] [Full Text]  
  • Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C., the Linezolid CSSTI Study Group, (2005). Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob. Agents Chemother. 49: 2260-2266 [Abstract] [Full Text]  
  • Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., Caillon, J. (2005). In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 45-51 [Abstract] [Full Text]  
  • Abbanat, D., Webb, G., Foleno, B., Li, Y., Macielag, M., Montenegro, D., Wira, E., Bush, K. (2005). In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides. Antimicrob. Agents Chemother. 49: 309-315 [Abstract] [Full Text]  
  • Curtin, J., Cormican, M., Fleming, G., Keelehan, J., Colleran, E. (2003). Linezolid Compared with Eperezolid, Vancomycin, and Gentamicin in an In Vitro Model of Antimicrobial Lock Therapy for Staphylococcus epidermidis Central Venous Catheter-Related Biofilm Infections. Antimicrob. Agents Chemother. 47: 3145-3148 [Abstract] [Full Text]  
  • Brier, M. E., Stalker, D. J., Aronoff, G. R., Batts, D. H., Ryan, K. K., O'Grady, M., Hopkins, N. K., Jungbluth, G. L. (2003). Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction. Antimicrob. Agents Chemother. 47: 2775-2780 [Abstract] [Full Text]  
  • Colca, J. R., McDonald, W. G., Waldon, D. J., Thomasco, L. M., Gadwood, R. C., Lund, E. T., Cavey, G. S., Mathews, W. R., Adams, L. D., Cecil, E. T., Pearson, J. D., Bock, J. H., Mott, J. E., Shinabarger, D. L., Xiong, L., Mankin, A. S. (2003). Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics. J. Biol. Chem. 278: 21972-21979 [Abstract] [Full Text]  
  • Rubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., Remington, J. (2003). Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies. Antimicrob. Agents Chemother. 47: 1824-1831 [Abstract] [Full Text]  
  • Smith, P. F., Birmingham, M. C., Noskin, G. A., Meagher, A. K., Forrest, A., Rayner, C. R., Schentag, J. J. (2003). Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 14: 795-801 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Donnio, P.-Y., Bugnon, D., Potel, G. (2003). In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 51: 857-864 [Abstract] [Full Text]  
  • Bobkova, E. V., Yan, Y. P., Jordan, D. B., Kurilla, M. G., Pompliano, D. L. (2003). Catalytic Properties of Mutant 23 S Ribosomes Resistant to Oxazolidinones. J. Biol. Chem. 278: 9802-9807 [Abstract] [Full Text]  
  • Alcala, L., Ruiz-Serrano, M. J., Perez-Fernandez Turegano, C., Garcia de Viedma, D., Diaz-Infantes, M., Marin-Arriaza, M., Bouza, E. (2003). In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs. Antimicrob. Agents Chemother. 47: 416-417 [Abstract] [Full Text]  
  • Grohs, P., Kitzis, M.-D., Gutmann, L. (2003). In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 418-420 [Abstract] [Full Text]  
  • Jacqueline, C., Batard, E., Perez, L., Boutoille, D., Hamel, A., Caillon, J., Kergueris, M.-F., Potel, G., Bugnon, D. (2002). In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 46: 3706-3711 [Abstract] [Full Text]  
  • Pascual, A., Ballesta, S., Garcia, I., Perea, E. J. (2002). Uptake and Intracellular Activity of Linezolid in Human Phagocytes and Nonphagocytic Cells. Antimicrob. Agents Chemother. 46: 4013-4015 [Abstract] [Full Text]  
  • Rana, B., Butcher, I., Grigoris, P., Murnaghan, C., Seaton, R. A., Tobin, C. M. (2002). Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 50: 747-750 [Abstract] [Full Text]  
  • Marshall, S. H., Donskey, C. J., Hutton-Thomas, R., Salata, R. A., Rice, L. B. (2002). Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46: 3334-3336 [Abstract] [Full Text]  
  • Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Sahm, D. F. (2002). Determining Linezolid's Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release. Antimicrob. Agents Chemother. 46: 1989-1992 [Abstract] [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
  • Gentry-Nielsen, M. J., Olsen, K. M., Preheim, L. C. (2002). Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 46: 1345-1351 [Abstract] [Full Text]  
  • Aoki, H., Ke, L., Poppe, S. M., Poel, T. J., Weaver, E. A., Gadwood, R. C., Thomas, R. C., Shinabarger, D. L., Ganoza, M. C. (2002). Oxazolidinone Antibiotics Target the P Site on Escherichiacoli Ribosomes. Antimicrob. Agents Chemother. 46: 1080-1085 [Abstract] [Full Text]  
  • Vera-Cabrera, L., Gomez-Flores, A., Escalante-Fuentes, W. G., Welsh, O. (2001). In Vitro Activity of PNU-100766 (Linezolid), a New Oxazolidinone Antimicrobial, against Nocardia brasiliensis. Antimicrob. Agents Chemother. 45: 3629-3630 [Abstract] [Full Text]  
  • Kenny, G. E., Cartwright, F. D. (2001). Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrob. Agents Chemother. 45: 2604-2608 [Abstract] [Full Text]  
  • Grif, K., Dierich, M. P., Pfaller, K., Miglioli, P. A., Allerberger, F. (2001). In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48: 209-217 [Abstract] [Full Text]  
  • Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., Bruss, J. B., Sams, J. P., Johnson, M. G., Sanders, P. E., Hauer, M. J., Fagerness, P. E., Stryd, R. P., Peng, G. W., Shobe, E. M. (2001). Pharmacokinetics, Metabolism, and Excretion of Linezolid following an Oral Dose of [14C]Linezolid to Healthy Human Subjects. Drug Metab. Dispos. 29: 1136-1145 [Abstract] [Full Text]  
  • Gemmell, C. G., participating investigators in France, Germany, Ho, o. b. o. (2001). Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 48: 47-52 [Abstract] [Full Text]  
  • Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., Noskin, G. A. (2001). Resistance to Linezolid: Characterization of Mutations in rRNA and Comparison of Their Occurrences in Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 45: 2154-2156 [Abstract] [Full Text]  
  • Oramas-Shirey, M. P., Buchanan, L. V., Dileto-Fang, C. L., Dailey, C. F., Ford, C. W., Batts, D. H., Gibson, J. K. (2001). Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 47: 349-352 [Abstract] [Full Text]  
  • Cercenado, E., Garcia-Garrote, F., Bouza, E. (2001). In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 47: 77-81 [Abstract] [Full Text]  
  • Cottagnoud, P., Gerber, C. M., Acosta, F., Cottagnoud, M., Neftel, K., Tauber, M. G. (2000). Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46: 981-985 [Abstract] [Full Text]  
  • Cetinkaya, Y., Falk, P., Mayhall, C. G. (2000). Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 13: 686-707 [Abstract] [Full Text]  
  • Xiong, L., Kloss, P., Douthwaite, S., Andersen, N. M., Swaney, S., Shinabarger, D. L., Mankin, A. S. (2000). Oxazolidinone Resistance Mutations in 23S rRNA of Escherichia coli Reveal the Central Region of Domain V as the Primary Site of Drug Action. J. Bacteriol. 182: 5325-5331 [Abstract] [Full Text]  
  • McNicholas, P. M., Najarian, D. J., Mann, P. A., Hesk, D., Hare, R. S., Shaw, K. J., Black, T. A. (2000). Evernimicin Binds Exclusively to the 50S Ribosomal Subunit and Inhibits Translation in Cell-Free Systems Derived from both Gram-Positive and Gram-Negative Bacteria. Antimicrob. Agents Chemother. 44: 1121-1126 [Abstract] [Full Text]  
  • Harwell, J. I., Brown, R. B. (2000). The Drug-Resistant Pneumococcus: Clinical Relevance, Therapy, and Prevention. Chest 117: 530-541 [Abstract] [Full Text]  
  • Schülin, T., Thauvin-Eliopoulos, C., Moellering, R. C. Jr., Eliopoulos, G. M. (1999). Activities of the Oxazolidinones Linezolid and Eperezolid in Experimental Intra-Abdominal Abscess Due to Enterococcus faecalis or Vancomycin-Resistant Enterococcus faecium. Antimicrob. Agents Chemother. 43: 2873-2876 [Abstract] [Full Text]  
  • Noskin, G. A., Siddiqui, F., Stosor, V., Hacek, D., Peterson, L. R. (1999). In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 43: 2059-2062 [Abstract] [Full Text]  
  • Moellering, R. C. Jr. (1999). A Novel Antimicrobial Agent Joins the Battle against Resistant Bacteria. ANN INTERN MED 130: 155-157 [Full Text]  
  • Swaney, S. M., Aoki, H., Ganoza, M. C., Shinabarger, D. L. (1998). The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria. Antimicrob. Agents Chemother. 42: 3251-3255 [Abstract] [Full Text]  
  • Murray, R. W., Schaadt, R. D., Zurenko, G. E., Marotti, K. R. (1998). Ribosomes from an Oxazolidinone-Resistant Mutant Confer Resistance to Eperezolid in a Staphylococcus aureus Cell-Free Transcription-Translation Assay. Antimicrob. Agents Chemother. 42: 947-950 [Abstract] [Full Text]  
  • Patel, U., Yan, Y. P., Hobbs, F. W. Jr., Kaczmarczyk, J., Slee, A. M., Pompliano, D. L., Kurilla, M. G., Bobkova, E. V. (2001). Oxazolidinones Mechanism of Action: Inhibition of the First Peptide Bond Formation. J. Biol. Chem. 276: 37199-37205 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»